BBLG · XBRL financial data
Bone Biologics financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (BBLG's year ends in late December)
| In millions of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 1,070 | — | — | — | — | — |
| Research and development | 0 | 0 | 2 | 7 | 2 | 1 |
| General and administrative | 0 | 1 | 2 | 3 | 2 | 2 |
| Total operating expenses | 1 | 1 | 4 | 9 | 4 | 3 |
| Operating income (loss) | (1) | (1) | (4) | (9) | (4) | (3) |
| Income tax expense (benefit) | 0 | 0 | — | — | — | — |
| Net income (loss) | (2) | (2) | (1) | (9) | (4) | (3) |
| Earnings per share, basic USD per share | — | (0.35) | (0.13) | (34.01) | (4.83) | (2.65) |
| Earnings per share, diluted USD per share | — | — | (31.15) | (34.01) | (4.83) | (2.65) |
| Weighted average shares, basic millions of shares | — | — | 0 | 0 | 2 | 1 |
| Weighted average shares, diluted millions of shares | — | — | 0 | 0 | 2 | 1 |
- † Share count changed about 1/3 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/31 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 6x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (BBLG's year ends in late December)
| In millions of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | — | 7 | 8 | 3 | 3 | 5 |
| Total current assets | — | — | 8 | 4 | 4 | 6 |
| Total assets | 0 | 7 | 8 | 4 | 4 | 6 |
| Accounts payable | 0 | — | — | — | — | — |
| Total current liabilities | 14 | 0 | 3 | 1 | 0 | 0 |
| Total liabilities | 14 | 0 | 3 | 1 | 0 | 0 |
| Accumulated deficit | (69) | (70) | (72) | (81) | (85) | (88) |
| Total stockholders' equity | (14) | 7 | 6 | 3 | 3 | 5 |
| Total liabilities and equity | 0 | 7 | 8 | 4 | 4 | 6 |
| Common shares outstanding (cover page) millions of shares | 31 | 10 | 17 | 1 | 3 | 2 |
- † Share count changed about 1/3 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/31 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 6x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (BBLG's year ends in late December)
| In millions of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (2) | (2) | (1) | (9) | (4) | (3) |
| Stock-based compensation | — | 0 | 0 | 0 | 0 | 0 |
| Net cash from operating activities | (0) | (1) | (4) | (10) | (4) | (3) |
| Proceeds from issuing common stock | — | 7 | 4 | 5 | 2 | 4 |
| Net cash from financing activities | 0 | 8 | 4 | 5 | 4 | 5 |
| Net change in cash | (0) | 7 | 1 | (5) | 0 | 2 |
- † Share count changed about 1/3 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/31 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 6x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Bone Biologics | 6.1 | not reported | (0.5)* | 3.4M | 9.8 quarters | 10-QSep 30, 2026 |
| ENvue Medical | 1.1 | 0.2 | (2.7)* | 11.1M | 0.4 quarters | 10-QJun 30, 2026 |
| SeaStar Medical Holding | 7 | 0.6 | (3)* | 4.4M | 2.3 quarters | 10-QJun 30, 2026 |
| Tenon Medical | 1.7 | 1.3 | (2.8)* | 667,047 | 0.6 quarters | 10-QJun 30, 2026 |
| Sintx Technologies | 3.6 | 0.5 | (2.8)* | 6.7M | 1.3 quarters | 10-QJun 30, 2026 |
| OSR Health | 1.5 | 0.3 | (2.4)* | 35.1M | 0.6 quarters | 10-QJun 30, 2026 |
| Adm Tronics Unlimited | 0.2 | not reported | (0) | 67.6M | 6.8 quarters | 10-QJun 30, 2026 |
| Retractable Technologies | 2.6 | 7.2 | (1.7)* | 29.9M | 1.5 quarters | 10-QJun 30, 2026 |
| Sonoma Pharmaceuticals | 5.3 | 6.4 | (0.6) | 4.8M | 8.2 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.